BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30013686)

  • 1. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
    Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
    Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
    Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
    Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
    Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
    Lajkó E; Hegedüs R; Mező G; Kőhidai L
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
    Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
    Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
    Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
    Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
    Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
    Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
    Schreier VN; Pethő L; Orbán E; Marquardt A; Petre BA; Mező G; Manea M
    PLoS One; 2014; 9(4):e94041. PubMed ID: 24718594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
    Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
    Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
    Schuster S; Biri-Kovács B; Szeder B; Farkas V; Buday L; Szabó Z; Halmos G; Mező G
    Beilstein J Org Chem; 2018; 14():756-771. PubMed ID: 29719573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.
    Schuster S; Biri-Kovács B; Szeder B; Buday L; Gardi J; Szabó Z; Halmos G; Mező G
    Pharmaceutics; 2018 Nov; 10(4):. PubMed ID: 30423956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
    Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
    Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
    Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
    J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
    Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
    Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
    J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy.
    Hegedüs R; Pauschert A; Orbán E; Szabó I; Andreu D; Marquardt A; Mező G; Manea M
    Biopolymers; 2015 May; 104(3):167-77. PubMed ID: 25753049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect.
    Schlage P; Mezo G; Orbán E; Bosze S; Manea M
    J Control Release; 2011 Dec; 156(2):170-8. PubMed ID: 21864594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.
    Szabó I; Manea M; Orbán E; Csámpai A; Bosze S; Szabó R; Tejeda M; Gaál D; Kapuvári B; Przybylski M; Hudecz F; Mezo G
    Bioconjug Chem; 2009 Apr; 20(4):656-65. PubMed ID: 19296605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
    Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.